Etanercept as prophylactic psoriatic therapy before interferon-α and ribavirin treatment for active hepatitis C infection

被引：21

作者：

Behnam, S. E. ^{[2
]}

Hindiyeh, R. ^{[3
]}

Fife, D. J. ^{[4
]}

Jeffes, E. W., III ^{[2
]}

Wu, J. J. ^{[1
]}

机构：

[1] Kaiser Permanente Los Angeles Med Ctr, Dept Dermatol, Los Angeles, CA 90027 USA

[2] Univ Calif Irvine, Dept Dermatol, Irvine, CA 92717 USA

[3] Univ Calif Irvine, Dept Internal Med, Irvine, CA USA

[4] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL USA

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2010年 / 35卷 / 04期

关键词：

VIRUS-INFECTION;

D O I：

10.1111/j.1365-2230.2009.03476.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P>Patients with psoriasis and chronic hepatitis C virus (HCV) infection are a therapeutic challenge. Systemic psoriasis treatment with methotrexate and acitretin can be hepatotoxic, and interferon (IFN)-alpha for treatment of HCV can worsen psoriasis. Etanercept can be successfully used in patients with psoriasis and HCV. To our knowledge, this is the first case report of etanercept used prophylactically to prevent a psoriatic flare in a patient with HCV treated with IFN-alpha and ribavirin.

引用

页码：397 / 398

页数：2

共 6 条

[1] Etanercept therapy in two patients with psoriasis and concomitant hepatitis C [J].

De Simone, Clara ;

Paradisi, Andrea ;

Capizzi, Rodolfo ;

Carbone, Angelo ;

Siciliano, Massimo ;

Amerio, Pier Luigi ;

Gemelli, Policlinico A. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (06) :1102-1104

[2] Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C [J].

Downs, AMR ;

Dunnill, MGS .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2000, 25 (04) :351-352

[3]

Khanna M, 2003, J Dermatolog Treat, V14, P229, DOI 10.1080/09546630310020470

[4] Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 cases [J].

Magliocco, MA ;

Gottlieb, AB .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (04) :580-584

[5] Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus [J].

Marotte, H. ;

Fontanges, E. ;

Bailly, F. ;

Zoulim, F. ;

Trepo, C. ;

Miossec, P. .

RHEUMATOLOGY, 2007, 46 (01) :97-99

[6] Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study [J].

Zein, NN .

JOURNAL OF HEPATOLOGY, 2005, 42 (03) :315-322

← 1 →